President & Chief Financial Officer
Mr. Brian Zietsman, our President and Chief Financial Officer, joined the Company in July 2013. He brings more than 20 years of strategic finance and accounting experience to his position, over half of which has been in the pharmaceutical industry for both public and private companies. Prior to joining Enteris BioPharma, Mr. Zietsman was the Chief Financial Officer of Unigene Laboratories, Inc. where he played a pivotal role in that company’s restructuring. Prior to working at Unigene, he was the Corporate Controller at Duff & Phelps (NYSE DUF) and between 2005 and 2011, he worked in various financial capacities at Enzon Pharmaceuticals, Inc., (NASDAQ – ENZN), including Vice President and Corporate Controller. Prior to Enzon, Mr. Zietsman was the Corporate Controller at Reliant Pharmaceuticals, Inc., a privately held company which was acquired by GlaxoSmithKline, and earlier worked at Deloitte where he held various positions of increasing responsibility, leaving as a Senior Manager in the audit group. Mr. Zietsman is a graduate from Rhodes University, South Africa where he earned his B. Com (Accounting), BSc (Computer Science) and HDIPACC certifications. Mr. Zietsman is a registered CPA.
Nozer Mehta, Ph.D.
Chief Scientific Officer
Dr. Nozer Mehta, our Chief Scientific Officer, joined the Company in July 2013. He brings more than 30 years of experience in all aspects of drug discovery, formulation and clinical development. Dr. Mehta previously served as the CSO of Unigene Laboratories, Inc. from August 2012 till June 2013 and as Vice President, R&D from March of 2005 through August of 2012. Previous to this, Dr. Mehta held positions of increasing responsibility at Unigene and played a key role in the development of the oral and nasal delivery and recombinant expression technologies that led to the creation of Enteris BioPharma’s drug delivery business. Dr. Mehta obtained a Doctoratd’Université degree (equivalent to a Ph.D.) with honors from the Université Louis Pasteur in Strasbourg, France in 1976. Prior to joining Unigene, Dr. Mehta worked at the Cancer Research Institute in Mumbai, India and at the University of Nebraska at Lincoln.
Vice President, Business Development
Mr. Tim Saxon, our Vice President, Business Development, joined the company in August 2013. Recently he has consulted for a number of companies including Soluble Therapeutics Inc. Until early 2012, he was VP Business Development at Arecor, a biotech start-up where he spent six years building collaborations with many of the leading global pharmaceutical companies. Prior to that, Mr. Saxon was Executive Director at Novartis and Assistant Vice President, Global Business Development at Wyeth (now Pfizer). Before moving to the US in 1999, Mr. Saxon worked in consulting at Sagentia, in Cambridge, UK and he had roles in marketing and in business development at Boots. At ICI (now AstraZeneca), Mr. Saxon held positions in international marketing, UK product management and medical sales. Mr. Saxon’s first jobs in ICI were as a Chemical Engineer. Mr. Saxon graduated with a B.Sc. in Chemical Engineering at Loughborough University of Technology, returning there mid-career to the Business School to gain his MBA with distinction.
Paul Shields, Ph.D.
Vice President, Operations
Dr. Paul Shields, our Vice President of Operations, joined the Company in July 2013. He brings more than 24 years of experience in the biopharmaceutical industry, focusing on Chemistry, Manufacturing and Controls (CMC) for a variety of products. Dr. Shields previously served as the Vice President, Manufacturing Operations for Unigene Laboratories from 2005 to 2013, where he managed commercial CMC operations for recombinant active ingredients, and clinical and commercial supplies of nasal spray and solid dose products. Prior to that, he served as Unigene’s Director of Plant Operations from 2001 through 2005, as Plant Manager from 1995 through 2001, and in various other capacities with Unigene from 1989 through 1995. Dr. Shields holds a Ph.D. in biochemistry from the University of Pennsylvania and a B.S. in chemical engineering from the University of Michigan.